Skip to main content

Andrew Robertson

Educational Background

  • Medical Physics Residency, BC Cancer, Canada (2021-2023)
  • PhD, Physics (Medical Physics Stream), University of British Columbia, BC, Canada (2020)
  • BSc, Physics, University of Victoria, BC, Canada (2013)

Publications

  • A. K. H. Robertson, B. L. McNeily, W. Fu, H. Yang, C. Hoehr, C. F. Ramogida, P. Scha er, Production, Purification, and Radiolabeling of the 212Pb/203Pb Theranostic Pair, EJNMMI Radiopharmacy and Chemistry 6 (2021)
  • A. K. H. Robertson, P. Kunz, C. Hoehr, P. Scha er, Nuclide Production Cross Sections from Irradiation of Thorium by 438 MeV Protons and a Comparison to FLUKA and GEANT4 Simulations, Physical Review C 102 (2020).
  • A. K. H. Robertson, B. L. McNeil, H. Yang, D. Gendron, R. Perron, V. Radchenko, S. Zeisler, P. Causey, P. Schafer,232Th-Spallation-Produced 225Ac with Reduced 227Ac Content, Inorganic Chemistry 59 (2020).
  • L. Li, J. Rousseau, M. G. Jaraquemada-Pelaez, X. Wang, A. Robertson, V. Radchenko, P. Scha er, K. Lin, F. Benard,C. Orvig, 225Ac-H4py4pa for Targeted Alpha Therapy, Bioconjugate Chemistry 31 (2020).
  • C. F. Ramogida, A. K. H. Robertson, U. Jermilova, C. Zhang, H. Yang, P. Kunz, J. Lassen, I. Bratanovic, V. Brown, L. Southcott, C. Rodriguez-Rodriguez, V. Radchenko, F. Benard, C. Orvig, P. Scha er, Evaluation of Polydentate Picolinic Acid Chelating Ligands and an Melanocyte-Stimulating Hormone Derivative for Targeted Alpha Therapy Using ISOL-Produced 225Ac, EJNMMI Radiopharmacy and Chemistry 4 (2019).
  • A. K. H. Robertson, A. Lobbezoo, L. Moskven, P. Scha er, C. Hoehr, Design of a Thorium Metal Target for 225Ac Production at TRIUMF, Instruments 3 (2019).
  • A. K. H. Robertson, C. F. Ramogida, P. Scha er, V. Radchenko, Development of 225Ac-Radiopharmaceuticals: TRIUMF Perspectives and Experiences, Current Radiopharmaceuticals 11 (2018).
  • A. K. H. Robertson, J. R. Crawfordy, H. Yang, C. Rodriguez-Rodriguez, P. L. Esquinas, P. Kunz, S. Blinder, V. Sossi, P. Scha er, T. J. Ruth, Evaluation of 209At as a Theranostic Isotope for 211At-Radiopharmaceutical Development Using High-Energy SPECT, Physics in Medicine and Biology 63 (2018).
  • N. Thiele, V. Brown, J. M. Kelly, A. Amor-Coarasa, U. Jermilova, S. N. MacMillan, A. Nikolopoulou, S. Ponnala, C. F. Ramogida, A. K. H. Robertson, C. Rodriguez-Rodriguez, P. Scha er, C. Williams, J. W. Babich, V. Radchenko, J. J. Wilson, An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy, Angewandte Chemie 56 (2017).
  • A. K. H. Robertson, C. F. Ramogida, C. Rodriguez-Rodriguez, S. Blinder, P. Kunz, V. Sossi, P. Scha er, Multi-Isotope SPECT Imaging of the 225Ac Decay Chain: Feasibility Studies, Physics in Medicine and Biology 62, (2016).




SOURCE: Andrew Robertson ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2022 Provincial Health Services Authority